Alligator, Scandion pursue preclinical immunotherapies

By The Science Advisory Board staff writers

June 4, 2020 -- Sweden-based Alligator Bioscience and Scandion Oncology inked an agreement to explore the antitumor efficacy of CD40 antibody mitazalimab in combination with SCO-101 and chemotherapy in preclinical tumor models.

The companies expect that SCO-101 will revert chemotherapy resistance and strengthen the antitumor effects of mitazalimab. The combination of immuno-oncology drugs with standard chemotherapy results in additive antitumor effects and more durable remissions in cancer patients.

Alligator's drug candidate mitazalimab enhances presentation of antigens released by cancer drugs and is proposed to be beneficial in combination with chemotherapy. Scandion's drug candidate SCO-101 acts by blocking resistance mechanisms in cancer cells by allowing chemotherapy to kill previously resistant cancer cells. SCO-101 would potentially restore the release of antigens and reactivate immune-oncology drugs.

Trio, Ajinomoto to develop cancer therapeutic
Cancer therapeutics company Trio Pharmaceuticals and biopharmaceutical contract development and manufacturing company Ajinomoto Bio-Pharma Services have...

Copyright © 2020

International Society for Cell and Gene Therapy Annual Meeting
May 4 - June 7
San Francisco, California United States
Interphex 2022 Conference
May 24-26
New York, New York United States
American Society for Mass Spectrometry Annual Conference
June 5-9
Minneapolis, Minnesota United States
American Society for Microbiology Microbe Meeting
June 9-13
District of Columbia United States
HPLC 2022
June 18-23
San Diego, California United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter